RET fusions, found in 1–2% of NSCLC cases, respond well to selective RET inhibitors, such as selpercatinib and pralsetinib, although resistance can occur via mechanisms like MET amplification. The gene discussed is RET; the disease is non-small cell lung carcinoma.